Battiwalla Minoo, Tichelli André, Majhail Navneet S
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Hematology, University Hospital, Basel, Switzerland.
Biol Blood Marrow Transplant. 2017 Mar;23(3S):S1-S9. doi: 10.1016/j.bbmt.2017.01.001.
The number of survivors after hematopoietic cell transplantation (HCT) is expected to dramatically increase over the next decade. Significant and unique challenges confront survivors for decades after their underlying indication (malignancy or marrow failure) has been cured by HCT. The National Institutes of Health (NIH) Late Effects Consensus Conference in June 2016 brought together international experts in the field to plan the next phase of survivorship efforts. Working groups laid out the roadmap for collaborative research and health care delivery. Potentially lethal late effects (cardiac/vascular, subsequent neoplasms, and infectious), patient-centered outcomes, health care delivery, and research methodology are highlighted here. Important recommendations from the NIH Consensus Conference provide fresh perspectives for the future. As HCT evolves into a safer and higher-volume procedure, this marks a time for concerted action to ensure that no survivor is left behind.
预计在未来十年内，造血细胞移植（HCT）后的幸存者数量将大幅增加。在潜在疾病指征（恶性肿瘤或骨髓衰竭）通过HCT治愈后的数十年里，幸存者面临着重大且独特的挑战。2016年6月，美国国立卫生研究院（NIH）召开了迟发效应共识会议，汇聚了该领域的国际专家，以规划下一阶段的生存研究工作。各工作组制定了合作研究和医疗服务的路线图。本文重点介绍了潜在致命的迟发效应（心脏/血管、后续肿瘤和感染）、以患者为中心的结局、医疗服务以及研究方法。NIH共识会议提出的重要建议为未来提供了新的视角。随着HCT发展成为一种更安全、实施量更大的治疗手段，这标志着需要采取一致行动，确保不让任何一位幸存者掉队。
Zotero 插件